$DYN
Dyne Therapeutics Inc

2021 Q2 Form 10-Q Financial Statement

#000156459021024523 Filed on May 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2021 Q1 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.293M $6.510M
YoY Change 102.67%
% of Gross Profit
Research & Development $23.87M $18.63M $6.089M
YoY Change 225.5% 205.88%
% of Gross Profit
Depreciation & Amortization $200.0K $200.0K $150.0K
YoY Change 0.0% 33.33%
% of Gross Profit
Operating Expenses $30.17M $25.13M $7.853M
YoY Change 247.72% 220.06%
Operating Profit -$30.17M -$25.13M -$7.853M
YoY Change 247.72% 220.06%
Interest Expense $210.0K $170.0K
YoY Change -231.25%
% of Operating Profit
Other Income/Expense, Net $210.0K $166.0K -$33.00K
YoY Change -168.4% -603.03%
Pretax Income -$29.96M -$24.97M
YoY Change 77.58%
Income Tax
% Of Pretax Income
Net Earnings -$29.96M -$24.97M -$7.886M
YoY Change 233.5% 216.61% 277.86%
Net Earnings / Revenue
Basic Earnings Per Share -$0.58
Diluted Earnings Per Share -$0.58 -$504.8K
COMMON SHARES
Basic Shares Outstanding 51.21M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q2 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $435.6M $483.1M
YoY Change 3622.98%
Cash & Equivalents $258.4M $310.9M $19.04M
Short-Term Investments $177.2M $172.1M
Other Short-Term Assets $25.71M $4.000M
YoY Change 12754.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $461.3M $487.1M
YoY Change 3776.45%
LONG-TERM ASSETS
Property, Plant & Equipment $2.589M $1.777M
YoY Change 72.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.885M $2.300M
YoY Change 1342.5%
Total Long-Term Assets $5.850M $4.642M
YoY Change 244.12%
TOTAL ASSETS
Total Short-Term Assets $461.3M $487.1M
Total Long-Term Assets $5.850M $4.642M
Total Assets $467.1M $491.7M
YoY Change 3334.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.649M $5.760M
YoY Change 156.77%
Accrued Expenses $8.902M $7.700M
YoY Change 368.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.55M $13.50M
YoY Change 254.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.55M $13.50M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $14.55M $13.45M
YoY Change 1.76%
SHAREHOLDERS EQUITY
Retained Earnings -$104.2M
YoY Change
Common Stock $6.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $452.6M $478.3M $8.188M
YoY Change
Total Liabilities & Shareholders Equity $467.1M $491.7M
YoY Change 3334.9%

Cashflow Statement

Concept 2021 Q2 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$29.96M -$24.97M -$7.886M
YoY Change 233.5% 216.61% 277.86%
Depreciation, Depletion And Amortization $200.0K $200.0K $150.0K
YoY Change 0.0% 33.33%
Cash From Operating Activities -$46.15M -$18.39M -$7.288M
YoY Change 216.12% 152.37%
INVESTING ACTIVITIES
Capital Expenditures -$737.0K $9.000K $211.0K
YoY Change 163.21% -95.73%
Acquisitions
YoY Change
Other Investing Activities -$5.692M -$128.4M
YoY Change
Cash From Investing Activities -$6.429M -$128.4M -$211.0K
YoY Change 2196.07% 60741.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 25.00K 157.3M 11.91M
YoY Change -99.79% 1220.54%
NET CHANGE
Cash From Operating Activities -46.15M -18.39M -7.288M
Cash From Investing Activities -6.429M -128.4M -211.0K
Cash From Financing Activities 25.00K 157.3M 11.91M
Net Change In Cash -52.56M 10.48M 4.409M
YoY Change 1675.57% 137.74%
FREE CASH FLOW
Cash From Operating Activities -$46.15M -$18.39M -$7.288M
Capital Expenditures -$737.0K $9.000K $211.0K
Free Cash Flow -$45.42M -$18.40M -$7.499M
YoY Change 217.15% 145.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6509000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1764000
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001818794
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
830 Winter Street
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51458066
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45446903
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51158276
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q1 us-gaap Liabilities
Liabilities
13450000
CY2020Q4 us-gaap Liabilities
Liabilities
10967000
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity File Number
EntityFileNumber
001-39509
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-4883909
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021Q1 dei Entity Shell Company
EntityShellCompany
true
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
CY2021Q1 dei City Area Code
CityAreaCode
781
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
786-8230
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Dyne Therapeutics, Inc.
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
51205932
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2021Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
172136000
CY2021Q1 dei Trading Symbol
TradingSymbol
DYN
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
300852000
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
310949000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
44462000
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3983000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3773000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
487068000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
349087000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1777000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1946000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
562000
CY2021Q1 dyn Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
2303000
CY2020Q4 dyn Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
2301000
CY2021Q1 us-gaap Assets
Assets
491710000
CY2020Q4 us-gaap Assets
Assets
353334000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5760000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3440000
CY2021Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7094000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7527000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
596000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
582473000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
421572000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-68000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
6000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-27000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104151000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79183000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
478260000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
342367000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
491710000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
353334000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
7853000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
66000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7886000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
157237000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3652000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
14036000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
8188000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-24968000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-128375000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-211000
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
157237000
CY2020Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
9936000
CY2020Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
1972000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45076574
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18625000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6089000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
25134000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25134000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7853000
CY2021Q1 us-gaap Interest Income Other
InterestIncomeOther
166000
CY2020Q1 us-gaap Interest Income Other
InterestIncomeOther
24000
CY2020Q1 us-gaap Interest Expense Other
InterestExpenseOther
57000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
166000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-24968000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-7886000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.90
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49472497
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8756513
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-41000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25009000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-7886000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3652000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
66000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
238000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
150000
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
12000
CY2021Q1 dyn Non Cash Lease Expense
NonCashLeaseExpense
-7000
CY2020Q1 dyn Non Cash Lease Expense
NonCashLeaseExpense
-2000
CY2021Q1 dyn Amortization Accretion Of Premium Discount On Marketable Securities
AmortizationAccretionOfPremiumDiscountOnMarketableSecurities
492000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-331000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
129000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
1869000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
501000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18393000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7288000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
211000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
132186000
CY2021Q1 dyn Maturities Of Marketable Securities
MaturitiesOfMarketableSecurities
3820000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
157250000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11908000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10482000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19041000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2301000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
59000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8000
CY2020Q1 dyn Issuance Costs From Convertible Preferred Stock Included In Accounts Payable Or Accrued Expenses
IssuanceCostsFromConvertiblePreferredStockIncludedInAccountsPayableOrAccruedExpenses
18000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4409000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
303153000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14632000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
313635000
CY2020Q1 dyn Cash Paid For Interest And Income Taxes
CashPaidForInterestAndIncomeTaxes
14000
CY2020Q4 dyn Fair Value Assets Transfers Amount
FairValueAssetsTransfersAmount
0
CY2021Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
119510000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
172136000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
59244000
CY2021Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-12-01
CY2021Q1 dyn Lease Term Description
LeaseTermDescription
The Company classifies leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use assets and current and non-current lease liabilities, as applicable on the balance sheet.
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 dyn Cash And Cash Equivalents Maturity Period
CashAndCashEquivalentsMaturityPeriod
P90D
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
2700000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
2300000
CY2021Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
383000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2303000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.44
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.68
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0079
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8810000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0088
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
313635000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
303153000
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
172204000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
78000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
44489000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
27000
CY2021Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
361930000
CY2021Q1 dyn Fair Value Assets Transfers Amount
FairValueAssetsTransfersAmount
0
CY2021Q1 dyn Available For Sale Debt Securities Maturing In One Year Through Two Years
AvailableForSaleDebtSecuritiesMaturingInOneYearThroughTwoYears
52626000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3010000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2941000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1233000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
995000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
779000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2105000
CY2021Q1 dyn Accrued Consulting Services Current
AccruedConsultingServicesCurrent
340000
CY2020Q4 dyn Accrued Consulting Services Current
AccruedConsultingServicesCurrent
263000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
131000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
325000
CY2021Q1 dyn Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5844000
CY2020Q4 dyn Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
4782000
CY2020Q4 dyn Accrued Facility Costs Current
AccruedFacilityCostsCurrent
52000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.74
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.75
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0113
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0167
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6421589
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
361000
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
11163
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6771426
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
822408
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6771426
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.97
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
17.70
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.20
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.55
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.34
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.55
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y3M18D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
90112000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
59244000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3652000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
66000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7560471
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12481436
CY2021Q1 dyn Lease Executed Date
LeaseExecutedDate
2019-07-01
CY2021Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-12-31
CY2020Q4 dyn Facility Additional Area Leased
FacilityAdditionalAreaLeased
68187
CY2020Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P8Y7M
CY2021Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company’s obligation for the payment of base rent for the Premises begins seven months after the commencement date and will be $0.4 million per month, increasing up to $0.5 million during the term of the Lease. The Company has two options to extend the term of the Lease, each for a period of an additional five years. The term of this lease will commence on the earlier of the date the Company commences its business operations on the Premises or the date the agreed upon improvements to the Premises are substantially completed and necessary occupancy permits are obtained. The Company expects the Premises to be ready for occupancy in the second half of 2021.
CY2020Q4 dyn Operating Lease Monthly Rent Expense
OperatingLeaseMonthlyRentExpense
400000
CY2020Q4 dyn Operating Lease Increase In Monthly Rent Expense
OperatingLeaseIncreaseInMonthlyRentExpense
500000
CY2020Q4 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Company has two options to extend the term of the Lease, each for a period of an additional five years
CY2020Q4 dyn Operating Lease Period Of Extension
OperatingLeasePeriodOfExtension
P5Y
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
190000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
114000
CY2021Q1 us-gaap Lease Cost
LeaseCost
304000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
197000
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9M18D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0325
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
603000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
603000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7000
CY2021Q1 us-gaap Area Of Land
AreaOfLand
68187
CY2021Q1 dyn Lease Commitment Expected Amount
LeaseCommitmentExpectedAmount
40900000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
800000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
4603000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4741000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4883000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
5029000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
21672000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
41728000

Files In Submission

Name View Source Status
0001564590-21-024523-index-headers.html Edgar Link pending
0001564590-21-024523-index.html Edgar Link pending
0001564590-21-024523.txt Edgar Link pending
0001564590-21-024523-xbrl.zip Edgar Link pending
dyn-10q_20210331.htm Edgar Link pending
dyn-20210331.xml Edgar Link completed
dyn-20210331.xsd Edgar Link pending
dyn-20210331_cal.xml Edgar Link unprocessable
dyn-20210331_def.xml Edgar Link unprocessable
dyn-20210331_lab.xml Edgar Link unprocessable
dyn-20210331_pre.xml Edgar Link unprocessable
dyn-ex101_63.htm Edgar Link pending
dyn-ex311_7.htm Edgar Link pending
dyn-ex312_6.htm Edgar Link pending
dyn-ex321_8.htm Edgar Link pending
dyn-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending